Roivant subsidiary Priovant's Phase 2 lupus study of oral brepocitinib fails primary endpoint

Roivant Sciences Ltd.

Oral brepocitinib did not meet primary endpoint of SRI-4 at Week 52 in moderate-to-severe active lupus.
Highest placebo response rate observed in any significant SLE study prevented differentiation; active arm showed high SRI-4 rates.
Priovant will not progress brepocitinib in SLE but continues in non-infectious uveitis and dermatomyositis.
Topline results for NIU Phase 2 expected Q1 2024; dermatomyositis Phase 3 topline in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.